New treatment strategies in advanced neuroendocrine tumours

Digestive and Liver Disease

Volumn 44, Issue 2, 2012, Pages 95-105

  Walter, Thomas ^a   Brixi Benmansour, Hedia ^b   Lombard Bohas, Catherine ^a   Cadiot, Guillaume ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

Antiangiogenic; Chemotherapy; Hepatic embolization; Somatostatin; Targeted therapy

Indexed keywords

2 METHOXYESTRADIOL; ALPHA2A INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE TRIPHOSPHATE; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PAZOPANIB; PEGINTERFERON; PLACEBO; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOID SYNDROME; CARDIOTOXICITY; CHEMOEMBOLIZATION; CRYOABLATION; DIARRHEA; DIGESTIVE SYSTEM TUMOR; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL NEUROENDOCRINE TUMOR; HAIR LOSS; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; LEUKOPENIA; LIVER METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PRACTICE GUIDELINES AS TOPIC;

EID: 84855747302     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.08.022     Document Type: Review

References (110)

1. Solcia E., Klöppel G., Sobin L. Histological typing of endocrine tumours 2000, Springer Verlag, New York. 2nd ed.
2. Bosman F.T., Carneiro F., Hruban R.H., et al. WHO classification of tumors of the digestive system 2010, IARC, Lyon. 4th ed.
3. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
4. Lepage C., Rachet B., Coleman M.P. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007, 132:899-904.
5. Rindi G., Klöppel G., Alhman H., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
6. Rindi G., Klöppel G., Couvelard A., et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451:757-762.
7. Sobin L., Gospodarowicz M., Wittekind C. TNM classification of malignant tumours 2010, UICC International Union Against Cancer, Wiley-Blackwell, Oxford.
8. Kulke M.H., Siu L.L., Tepper J.E., et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 2011, 29:934-943.
9. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
10. Auernhammer C.J., Goke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011, 60:1009-1021.
11. Oberg K., Ferone D., Kaltsas G., et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology 2009, 90:209-213.
12. Modlin I.M., Pavel M., Kidd M., et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2011, 31:169-188.
13. Arnold R., Wied M., Behr T.H. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002, 3:643-656.
14. Kulke M.H., Stuart K., Earle C.C., et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006, 24. Abstract 4044.
15. Kulke M.H., Bergsland E.K., Yao J.C. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009, 360:195-197.
16. Steinmuller T., Kianmanesh R., Falconi M., et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008, 87:47-62.
17. Gurusamy K.S., Pamecha V., Sharma D., et al. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009, CD007118.
18. Kianmanesh R., Sauvanet A., Hentic O., et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 2008, 247:659-665.
19. Elias D., Goere D., Leroux G., et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 2009, 35:1092-1097.
20. Akyildiz H.Y., Mitchell J., Milas M., et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010, 148:1288-1293. discussion 93.
21. Saxena A., Chua T.C., Sarkar A., et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011, 149:209-220.
22. Cho C.S., Labow D.M., Tang L., et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 2008, 113:126-134.
23. Elias D., Lefevre J.H., Duvillard P., et al. Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think. Ann Surg 2010, 251:307-310.
24. Maire F., Hammel P., Faivre S., et al. Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology 2009, 90:67-72.
25. Clark O.H., Benson A.B., Berlin J.D., et al. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Canc Netw 2009, 7:712-747.
26. Boudreaux J.P., Klimstra D.S., Hassan M.M., et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 2010, 39:753-766.
27. Bettini R., Mantovani W., Boninsegna L., et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009, 41:49-55.
28. Mathe Z., Tagkalos E., Paul A., et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation 2011, 91:575-582.
29. Le Treut Y.P., Gregoire E., Belghiti J., et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008, 8:1205-1213.
30. Strosberg J.R., Cheema A., Kvols L.K. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011, 18:127-137.
31. Mayo S.C., de Jong M.C., Bloomston M., et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011, (June). [Epub ahead of print].
32. Marrache F., Vullierme M.P., Roy C., et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 2007, 96:49-55.
33. Dong X.D., Carr B.I. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011, (November). [Epub ahead of print].
34. Vogl T.J., Gruber T., Naguib N.N., et al. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol 2009, 193:941-947.
35. de Baere T., Deschamps F., Teriitheau C., et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008, 19:855-861.
36. Gaur S.K., Friese J.L., Sadow C.A., et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011, 34:566-572.
37. Strosberg J., Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010, 16:2963-2970.
38. Rinke A., Muller H.H., Schade-Brittinger C., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27:4656-4663.
39. Dahan L., Bonnetain F., Rougier P., et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009, 16:1351-1361.
40. Fazio N., de Braud F., Delle Fave G., et al. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. Ann Oncol 2007, 18:13-19.
41. Pavel M.E., Baum U., Hahn E.G., et al. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006, 26:8-13.
42. Kwekkeboom D.J., de Herder W.W., Krenning E.P. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011, 40:173-185.
43. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011, 29:2416-2423.
44. Kunikowska J., Krolicki L., Hubalewska-Dydejczyk A., et al. Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?. Eur J Nucl Med Mol Imaging 2011, (May). [Epub ahead of print].
45. Hentic O., Couvelard A., Rebours V., et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 2010, 18:51-59.
46. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326:519-523.
47. Delaunoit T., Ducreux M., Boige V., et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?. Eur J Cancer 2004, 40:515-520.
48. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22:4762-4771.
49. Cheng P.N., Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999, 86:944-948.
50. McCollum A.D., Kulke M.H., Ryan D.P., et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004, 27:485-488.
51. Fjallskog M.L., Janson E.T., Falkmer U.G., et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008, 88:53-58.
52. Turner N.C., Strauss S.J., Sarker D., et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010, 102:1106-1112.
53. Strosberg J.R., Fine R.L., Choi J., et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117:268-275.
54. Kulke M.H., Hornick J.L., Frauenhoffer C., et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009, 15:338-345.
55. Ekeblad S., Sundin A., Janson E.T., et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13:2986-2991.
56. Walter T., Bruneton D., Cassier P.A., et al. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. Clin Colorectal Cancer 2010, 9:248-254.
57. Brixi-Benmansour H., Jouve J., Mitry E., et al. Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma (FFCD 0302). Dig Liv Dis 2011, 43:912-916.
58. Sun W., Lipsitz S., Catalano P., et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005, 23:4897-4904.
59. Terris B., Scoazec J.Y., Rubbia L., et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998, 32:133-138.
60. Yao J.C., Phan A., Hoff P.M., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26:1316-1323.
61. Kunz P.L., Kuo T., Kaiser H.L., et al. A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results. J Clin Oncol 2008, 26. Abstract 15502.
62. Kulke M.H., Chan J.A., Meyerhardt J.A., et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2010, (October). [Epub ahead of print].
63. Besig S., Voland P., Baur D.M., et al. Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids. Neuroendocrinology 2009, 90:402-415.
64. Varker K.A., Campbell J., Shah M.H. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008, 61:661-668.
65. Kulke M.H., Bergsland E.K., Ryan D.P., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006, 24:3555-3561.
66. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24:401-406.
67. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
68. Hobday T.J., Rubin J., Holen K., et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C). J Clin Oncol 2007, 25. Abstract 4504.
69. Phan A.T., Yao J.C., Fogelman D.R., et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010, 28. Abstract 4001.
70. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:501-513.
71. Raymond E., Niccoli P., Raoul J., et al. Updated overall survival and progression-free survival by blinded independent central review of sunitinib versus placebo for patients with advanced unresectable pancreatic neuroendocrine tumors. J Clin Oncol 2011, 29. Abstract 4008.
72. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
73. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95:1148-1154.
74. Yao J.C., Phan A.T., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26:4311-4318.
75. Yao J.C., Lombard-Bohas C., Baudin E., et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28:69-76.
76. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523.
77. Pavel M.E., Hainsworth J., Baudin E., et al. A randomized, phase III trial of everolimus+octreotide LAR vs placebo+octreotide LAR in patients with advanced neuroendocrine tumours (NET) (RADIANT-2). Ann Oncol 2010, 21. Abstract LBA8.
78. Eriksson B., Klöppel G., Krenning E., et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008, 87:8-19.
79. Ramage J.K., Goretzki P.E., Manfredi R., et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008, 87:31-39.
80. Falconi M., Plockinger U., Kwekkeboom D.J., et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006, 84:196-211.
81. Kulke M.H., Anthony L.B., Bushnell D.L., et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010, 39:735-752.
82. Anthony L.B., Strosberg J.R., Klimstra D.S., et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETs): well-differentiated nets of the distal colon and rectum. Pancreas 2010, 39:767-774.
83. Oberg K., Akerstrom G., Rindi G., et al. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 21:S223-S227.
84. Dominguez S., Denys A., Madeira I., et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 2000, 12:151-157.
85. Gupta S., Yao J.C., Ahrar K., et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003, 9:261-267.
86. Loewe C., Schindl M., Cejna M., et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003, 180:1379-1384.
87. Roche A., Girish B.V., de Baere T., et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 2004, 51:1751-1756.
88. Strosberg J.R., Choi J., Cantor A.B., et al. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006, 13:72-78.
89. Granberg D., Eriksson L.G., Welin S., et al. Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors. Acta Radiol 2007, 48:180-185.
90. Ho A.S., Picus J., Darcy M.D., et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007, 188:1201-1207.
91. Whitney R., Valek V., Fages J.F., et al. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist 2011, 16:594-601.
92. King J., Quinn R., Glenn D.M., et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008, 113:921-929.
93. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008, 247:1029-1035.
94. 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008, 31:271-279.
95. Valkema R., De Jong M., Bakker W.H., et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002, 32:110-122.
96. Anthony L.B., Woltering E.A., Espenan G.D., et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002, 32:123-132.
97. Nguyen C., Faraggi M., Giraudet A.L., et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 2004, 45:1660-1668.
98. Delpassand E.S., Sims-Mourtada J., Saso H., et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm 2008, 23:292-300.
99. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002, 66:393-398.
100. 90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006, 36:147-156.
101. 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006, 26:703-707.
102. Cwikla J.B., Sankowski A., Seklecka N., et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 2010, 21:787-794.
103. Pfeifer A.K., Gregersen T., Gronbaek H., et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011, 93:189-196.
104. 177Lu-DOTA 0,Tyr3] octreotate: efficacy, and survival. J Clin Oncol 2008, 26:2124-2130.
105. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010, 28:1652-1659.
106. Ramanathan R.K., Cnaan A., Hahn R.G., et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001, 12:1139-1143.
107. Bajetta E., Ferrari L., Procopio G., et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002, 13:614-621.
108. Bajetta E., Catena L., Procopio G., et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol 2007, 59:637-642.
109. Cassier P.A., Walter T., Eymard B., et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 2009, 115:3392-3399.
110. Ducreux M.P., Boige V., Leboulleux S., et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology 2006, 70:134-140.